Search
Search
ASRS: 2025
Avni P. Finn, MD, MBA
Show Description +
Dr. Finn discusses data from the DAVIO 2 phase 2 trial of EYP-1901 for the treatment of wet AMD and whether the novel therapy reduces treatment burden compared with aflibercept (Eylea, Regeneron).
Posted: 8/06/2025
Avni P. Finn, MD, MBA
Dr. Finn discusses data from the DAVIO 2 phase 2 trial of EYP-1901 for the treatment of wet AMD and whether the novel therapy reduces treatment burden compared with aflibercept (Eylea, Regeneron).
Posted: 8/06/2025
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASRS: 2025.
Please log in to leave a comment.